Cutler Group’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-1,800
| Closed | -$183K | – | 4499 |
|
|
2023
Q2 | $183K | Buy |
1,800
+800
| +80% | +$75.7K | 0.03% | 646 |
|
|
2023
Q1 | $90K | Sell |
1,000
-5,000
| -83% | -$293K | 0.01% | 1032 |
|
|
2022
Q4 | $227K | Buy |
6,000
+1,946
| +48% | +$67K | 0.02% | 732 |
|
|
2022
Q3 | $101K | Sell |
4,054
-732
| -15% | -$20.3K | 0.01% | 1386 |
|
|
2022
Q2 | $145K | Sell |
4,786
-5,216
| -52% | -$156K | 0.01% | 1203 |
|
|
2022
Q1 | $327K | Buy |
10,002
+5,170
| +107% | +$153K | 0.02% | 889 |
|
|
2021
Q4 | $127K | Buy |
4,832
+3,532
| +272% | +$273K | 0.01% | 1670 |
|
|
2021
Q3 | $130K | Buy |
1,300
+946
| +267% | +$111K | 0.01% | 1706 |
|
|
2021
Q2 | $50K | Sell |
354
-506
| -59% | -$57.1K | ﹤0.01% | 2492 |
|
|
2021
Q1 | $85K | Buy |
+860
| New | +$100K | ﹤0.01% | 1905 |
|
|
2020
Q4 | – | Sell |
-3,400
| Closed | -$447K | – | 5683 |
|
|
2020
Q3 | $331K | Buy |
3,400
+3,240
| +2,025% | +$405K | 0.02% | 689 |
|
|
2020
Q2 | $24K | Buy |
+160
| New | +$24.3K | ﹤0.01% | 2263 |
|
|
2020
Q1 | – | Sell |
-61
| Closed | -$11.8K | – | 4845 |
|
|
2019
Q4 | $12K | Buy |
+61
| New | +$11.1K | ﹤0.01% | 2558 |
|
|
2019
Q3 | – | Sell |
-3,825
| Closed | -$325K | – | 4872 |
|
|
2019
Q2 | $360K | Buy |
3,825
+200
| +6% | +$17.3K | 0.03% | 449 |
|
|
2019
Q1 | $309K | Buy |
3,625
+2,825
| +353% | +$235K | 0.03% | 479 |
|
|
2018
Q4 | $44K | Buy |
+800
| New | +$48.8K | ﹤0.01% | 1565 |
|
|
2018
Q3 | – | Sell |
-500
| Closed | -$35.2K | – | 4876 |
|
|
2018
Q2 | $17K | Hold |
500
| – | – | ﹤0.01% | 2316 |
|
|
2018
Q1 | $10K | Buy |
500
+100
| +25% | +$2.57K | ﹤0.01% | 2818 |
|
|
2017
Q4 | $11K | Buy |
+400
| New | +$11.2K | ﹤0.01% | 3076 |
|
Other funds holding RETA
Cutler Group's RETA Position: Q3 2023 in Review
Cutler Group sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 1,800 shares — an estimated $183K sold.
Cutler Group first reported a position in RETA in Q4 2017 and held it in 19 quarters. The position peaked at $360K in Q2 2019. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.
- Cutler Group reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
- Cutler Group sold 1,800 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $183K.
- Cutler Group first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q4 2017 and held it in 19 quarters.
- Cutler Group's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $360K in Q2 2019.
- 2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.
Based on Cutler Group's 13F filing for Q3 2023, filed 7 Nov 2023.